Yang Xue-Jiao, Wu Yong-Juan, Wang Jing-Zhong, Zheng Yu-Lan, Li Xiao-Qi
Department of Respiratory and Critical Care Medicine, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Department of Interventional Radiology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, China.
Front Med (Lausanne). 2025 Apr 3;12:1524248. doi: 10.3389/fmed.2025.1524248. eCollection 2025.
Lung squamous cell carcinoma (SCC) is a subtype of non-small cell lung cancer with high incidence and mortality rates. While chemotherapy and immune checkpoint inhibitors (ICIs) have become crucial treatment options for SCC, these may be associated with unforeseen complications. Here, we present a 65-year-old male of hemoptysis caused by a pulmonary artery pseudoaneurysm (PAP) after chemotherapy combined with tislelizumab for lung SCC. After confirmation with angiography, successful embolization was performed to occlude the pseudoaneurysm and proximal artery. To our knowledge, this is the first reported case of PAP formation after chemotherapy combined with tislelizumab for lung SCC.
肺鳞状细胞癌(SCC)是一种发病率和死亡率都很高的非小细胞肺癌亚型。虽然化疗和免疫检查点抑制剂(ICIs)已成为SCC的关键治疗选择,但这些治疗可能会带来一些意想不到的并发症。在此,我们报告一例65岁男性,在接受化疗联合替雷利珠单抗治疗肺SCC后,因肺动脉假性动脉瘤(PAP)导致咯血。经血管造影确认后,成功进行了栓塞术以闭塞假性动脉瘤和近端动脉。据我们所知,这是首例关于化疗联合替雷利珠单抗治疗肺SCC后发生PAP的报道病例。